首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1606457

糖尿病视网膜病变治疗市场，按糖尿病视网膜病变类型、治疗类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Diabetic Retinopathy Therapeutic Market, By Diabetic Retinopathy Type, By Treatment Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: 2024年11月04日 | 出版商:

AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格

简介目录

报告要点

2023年，糖尿病视网膜病变治疗市场规模为91.0932亿美元，2024年至2032年复合年增长率为6.88%。

糖尿病视网膜病变治疗市场-市场动态

糖尿病和糖尿病视网膜病变盛行率不断上升，推动市场需求

全球糖尿病发生率不断上升，导致越来越多的人罹患糖尿病视网膜病变。据美国疾病管制与预防中心 (CDC) 称，到 2021 年，美国各年龄层估计有 960 万人患有糖尿病视网膜病变。然而，治疗方案的复杂性和治疗的潜在副作用可能会阻碍患者坚持治疗按照他们规定的治疗计划。相反，糖尿病视网膜病变治疗方面正在进行的研究和技术进步预计将促进市场成长。此外，人们对糖尿病患者定期眼科检查重要性的认识不断提高，为糖尿病视网膜病变治疗市场的成长提供了机会。

糖尿病视网膜病变治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 6.88% 左右的复合年增长率成长

根据糖尿病视网膜病变类型细分，预计非增殖性糖尿病视网膜病变将在 2023 年显示最大的市场份额

根据治疗类型细分，抗血管内皮生长因子（VGEF）药物是2023年的主导细分市场

按地区划分，北美糖尿病视网膜病变治疗市场是 2023 年主要的收入来源

糖尿病视网膜病变治疗市场-細項分析：

全球糖尿病视网膜病变治疗市场根据糖尿病视网膜病变类型、治疗类型、最终用户和地区进行细分。

根据糖尿病视网膜病变类型，市场分为两类：增殖性糖尿病视网膜病变和非增殖性糖尿病视网膜病变。非增殖性糖尿病视网膜病变领域主导市场。这主要是由于糖尿病患者的盛行率较高，以及人们对早期检测和治疗方案的认识和可用性不断提高。

根据最终用户，市场分为四大类：眼科中心、医院、门诊手术中心等。医院产业在市场中占据主导地位，并可能在预测期内保持其主导地位。这种主导地位主要是由医院提供全面护理的能力推动的，包括先进的诊断工具和手术干预，这对于有效管理糖尿病视网膜病变至关重要。

糖尿病视网膜病变治疗市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。

糖尿病视网膜病变治疗市场-竞争格局：

糖尿病视网膜病变盛行率的不断上升正在推动竞争格局的发展，其特点是创新的治疗策略和对全面患者护理的关注。该公司正在利用远距医疗和数位健康解决方案等先进技术来增强患者参与度并改善获得护理的机会。此外，许多组织正在优先考虑研究和开发，以推出针对糖尿病视网膜病变不同阶段的新疗法，从而解决未满足的医疗需求。与医疗保健提供者和研究机构的合作和伙伴关係也是常见策略，使公司能够扩大市场范围并改善治疗结果。

市场片段
- 以糖尿病视网膜病变类型分類的糖尿病视网膜病变治疗市场片段
- 按治疗类型分類的糖尿病视网膜病变治疗市场片段
- 最终使用者的糖尿病视网膜病变治疗市场片段
- 按国家/地区分類的糖尿病视网膜病变治疗市场片段
- 按地区分類的糖尿病视网膜病变治疗市场片段
竞争洞察

第 3 章：糖尿病视网膜病变治疗的主要市场趋势

糖尿病视网膜病变治疗市场驱动因素
- 市场驱动因素的影响分析
糖尿病视网膜病变治疗市场限制
- 市场限制影响分析
糖尿病视网膜病变治疗市场机会
糖尿病视网膜病变治疗市场未来趋势

第 4 章：糖尿病视网膜病变治疗产业研究

PEST分析
波特五力分析
成长前景图
规范架构分析

第 5 章：糖尿病视网膜病变治疗市场：地缘政治紧张局势升级的影响

COVID-19 大流行的影响
俄罗斯-乌克兰战争的影响
中东衝突的影响

第 6 章：糖尿病视网膜病变治疗市场格局

2023 年糖尿病视网膜病变治疗市占分析
按主要製造商分類的故障数据
- 既定玩家分析
- 新兴玩家分析

第 7 章：糖尿病视网膜病变治疗市场 - 依糖尿病视网膜病变类型

概述
- 按糖尿病视网膜病变类型分類的细分市场份额分析
- 增殖性糖尿病视网膜病变
- 非增殖性糖尿病视网膜病变

第 8 章：糖尿病视网膜病变治疗市场 - 依治疗类型

概述
- 按治疗类型分類的细分市场份额分析
- 雷射手术
- 抗血管内皮生长因子（VEGF）药物
- 眼内类固醇注射
- 玻璃体切除术

第 9 章：糖尿病视网膜病变治疗市场 - 依最终用户

概述
- 按最终用户分類的细分市场占有率分析
- 眼科中心
- 医院
- 门诊手术中心
- 其他的

第 10 章：糖尿病视网膜病变治疗市场 - 按地理位置

介绍
- 按地理位置分類的细分市场占有率分析
北美洲
- 概述
- 北美糖尿病视网膜病变治疗主要製造商
- 北美市场规模和预测（按国家）
- 北美市场规模与预测（按糖尿病视网膜病变类型）
- 北美市场规模和预测（按治疗类型）
- 北美市场规模和预测（按最终用户）
- 我们
- 加拿大
欧洲
- 概述
- 欧洲糖尿病视网膜病变治疗主要製造商
- 欧洲市场规模和预测（按国家）
- 欧洲市场规模与预测（按糖尿病视网膜病变类型）
- 欧洲市场规模和预测（按治疗类型）
- 欧洲市场规模和预测（按最终用户）
- 德国
- 义大利
- 英国
- 法国
- 俄罗斯
- 荷兰
- 瑞典
- 波兰
- 欧洲其他地区
亚太地区 (APAC)
- 概述
- 亚太地区糖尿病视网膜病变治疗主要製造商
- 亚太地区市场规模与预测（按国家）
- 亚太地区市场规模与预测（依糖尿病视网膜病变类型）
- 亚太地区市场规模与预测（按治疗类型）
- 亚太地区市场规模和预测（按最终用户）
- 印度
- 中国
- 日本
- 韩国
- 澳洲
- 泰国
- 印尼
- 菲律宾
- 亚太地区其他地区
拉丁美洲
- 概述
- 拉丁美洲糖尿病视网膜病变治疗主要製造商
- 拉丁美洲市场规模与预测（按国家）
- 拉丁美洲市场规模与预测（按糖尿病视网膜病变类型）
- 拉丁美洲市场规模与预测（按治疗类型）
- 拉丁美洲市场规模和预测（按最终用户）
- 巴西
- 墨西哥
- 阿根廷
- 哥伦比亚
- 拉丁美洲其他地区
中东和非洲
- 概述
- 中东和非洲糖尿病视网膜病变治疗主要製造商
- 中东和非洲市场规模及预测（按国家）
- 中东和非洲市场规模及预测（依糖尿病视网膜病变类型）
- 中东和非洲市场规模及预测（按治疗类型）
- 中东和非洲市场规模及预测（按最终用户）
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 以色列
- 土耳其
- 阿尔及利亚
- 埃及
- MEA 的其余部分

第 11 章：主要供应商分析 - 糖尿病视网膜病变治疗产业

竞争仪表板
- Competitive Benchmarking
- Competitive Positioning
公司简介
- F. Hoffmann-La Roche Ltd.
- Abbott
- Alimera Sciences
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Oxurion NV
- ABBVIE INC.
- Sirnaomics
- Ampio Pharmaceuticals Inc.
- BCNPeptides
- Genentech, Inc.
- Kowa Company Ltd.
- Aurobindo Pharma
- Bausch Health Companies Inc.
- Accord Healthcare
- Regeneron Pharmaceuticals Inc.
- Lumenis Be Ltd.
- Glycadia, Inc.
- Others

第 12 章：360 度分析师视角

第 13 章：附录

研究方法
参考
缩写
免责声明
联络我们

简介目录

Product Code: ANV4172

REPORT HIGHLIGHT

Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.

Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.

Diabetic Retinopathy Therapeutic Market- Market Dynamics

Increasing prevalence of diabetes and diabetic retinopathy to propel market demand

The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.

Diabetic Retinopathy Therapeutic Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)

Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023

Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023

On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023

Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:

The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.

The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.

The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.

Diabetic Retinopathy Therapeutic Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Retinopathy Therapeutic Market- Competitive Landscape:

The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.

Recent Developments:

In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd.
Abbott
Alimera Sciences
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Oxurion NV
ABBVIE INC.
Sirnaomics
Ampio Pharmaceuticals Inc.
BCNPeptides
Genentech, Inc.
Kowa Company Ltd.
Aurobindo Pharma
Bausch Health Companies Inc.
Accord Healthcare
Regeneron Pharmaceuticals Inc.
Lumenis Be Ltd.
Glycadia, Inc.
Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032

Proliferative Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Laser Surgery
Anti-vascular Endothelial Growth Factor (VEGF) Drug
Intraocular Steroid Injection
Vitrectomy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Ophthalmic Centers
Hospitals
Ambulatory Surgery Centers
Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Diabetic Retinopathy Therapeutic Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Diabetic Retinopathy Therapeutic Market Snippet by Diabetic Retinopathy Type
- 2.1.2. Diabetic Retinopathy Therapeutic Market Snippet by Treatment Type
- 2.1.3. Diabetic Retinopathy Therapeutic Market Snippet by End User
- 2.1.4. Diabetic Retinopathy Therapeutic Market Snippet by Country
- 2.1.5. Diabetic Retinopathy Therapeutic Market Snippet by Region
2.2. Competitive Insights

3. Diabetic Retinopathy Therapeutic Key Market Trends

3.1. Diabetic Retinopathy Therapeutic Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Diabetic Retinopathy Therapeutic Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Diabetic Retinopathy Therapeutic Market Opportunities
3.4. Diabetic Retinopathy Therapeutic Market Future Trends

4. Diabetic Retinopathy Therapeutic Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Diabetic Retinopathy Therapeutic Market Landscape

6.1. Diabetic Retinopathy Therapeutic Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Diabetic Retinopathy Type, 2023 & 2032 (%)
- 7.1.2. Proliferative Diabetic Retinopathy
- 7.1.3. Non-proliferative Diabetic Retinopathy

8. Diabetic Retinopathy Therapeutic Market - By Treatment Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
- 8.1.2. Laser Surgery
- 8.1.3. Anti-vascular Endothelial Growth Factor (VEGF) Drug
- 8.1.4. Intraocular Steroid Injection
- 8.1.5. Vitrectomy

9. Diabetic Retinopathy Therapeutic Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 9.1.2. Ophthalmic Centers
- 9.1.3. Hospitals
- 9.1.4. Ambulatory Surgery Centers
- 9.1.5. Others

10. Diabetic Retinopathy Therapeutic Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Diabetic Retinopathy Therapeutic Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.2. Abbott
- 11.2.3. Alimera Sciences
- 11.2.4. Novartis AG
- 11.2.5. Pfizer Inc.
- 11.2.6. Regeneron Pharmaceuticals, Inc.
- 11.2.7. Bayer AG
- 11.2.8. Oxurion NV
- 11.2.9. ABBVIE INC.
- 11.2.10. Sirnaomics
- 11.2.11. Ampio Pharmaceuticals Inc.
- 11.2.12. BCNPeptides
- 11.2.13. Genentech, Inc.
- 11.2.14. Kowa Company Ltd.
- 11.2.15. Aurobindo Pharma
- 11.2.16. Bausch Health Companies Inc.
- 11.2.17. Accord Healthcare
- 11.2.18. Regeneron Pharmaceuticals Inc.
- 11.2.19. Lumenis Be Ltd.
- 11.2.20. Glycadia, Inc.
- 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格